SILO PHARMA INC (SILO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.40-2.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SILO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Raise capital through private placement of common stock and issuance of warrants to support working capital and corporate purposes.
Newly stated in 2026-Q2. The company announced a private placement expected to raise approximately $4 million upfront and up to $7.7 million more from warrant exercises, totaling potential gross proceeds of $11.7 million. This capital raise is a new priority with no prior quarters stating it, and the financial event matches management's stated intent.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules”
Maintain compliance with Nasdaq listing rules, specifically the minimum bid price requirement, to ensure continued listing on Nasdaq Capital Market.
Newly stated in 2026-Q2. Management confirmed regaining compliance with Nasdaq minimum bid price requirements as of June 17, 2026, ensuring continued listing on Nasdaq Capital Market. This priority is newly stated with no prior quarters mentioning it, and the regulatory milestone has been achieved.
“Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement”
Progress development of lead drug SPC-15 for PTSD and AI agents platform QwikAgents toward clinical trials and commercialization.
Newly stated in 2026-Q2. Management highlighted ongoing progress toward clinical trial initiation for SPC-15 and advancement of the AI platform QwikAgents. No prior quarters mention this priority, and no specific financial or milestone data is provided to assess delivery trajectory.
“Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 and advancing our AI agents platform QwikAgents.”
Implement a stock repurchase program authorized up to $1 million to manage capital allocation and shareholder value.
Newly stated in 2026-Q1. Management announced a stock repurchase program authorized for up to $1 million. There is no evidence of repurchase activity or changes in capital allocation since the announcement, so delivery status is limited progress.
“Board of Directors approved a stock repurchase program authorizing purchase of up to $1 million of common stock.”
Acquire complementary technologies and assets to broaden the company’s biopharmaceutical and AI platform capabilities.
Newly stated in 2026-Q1. Management disclosed an acquisition of software and domain assets for the QwikAgents AI platform, indicating strategic expansion. No prior quarters mention acquisitions, and no financial impact is reported yet, so delivery is early stage.
“Entered into an asset purchase agreement to acquire software and domain names for QwikAgents platform.”
Over the trailing year it converted 0.92x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
20 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.